A multi-arm, multi-stage, randomized phase II/III trial of immunotherapy strategies in metastatic hormone-sensitive prostate cancer
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Docetaxel (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Hormone inhibitors
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PROSTRATEGY
Most Recent Events
- 24 Oct 2023 Results assessing the feasibility and safety of androgen deprivation therapy plus docetaxel with or without nivolumab or ipilimumab-nivolumab in high-volume metastatic hormone-sensitive prostate cancer, presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Results reporting feasibility, safety and efficacy outcomes data from pilot phase with a median follow-up of 32.5 months presented at the 48th European Society for Medical Oncology Congress
- 25 Sep 2023 This trial has been completed, according to European Clinical Trials Database record